首页> 外文期刊>International journal of colorectal disease. >Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis
【24h】

Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis

机译:碳水化合物抗原19-9是具有正常水平的癌胚抗原的结直肠癌患者的重要预后因素,可能有助于预测肺转移

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose: We retrospectively analyzed preoperative levels of carbohydrate antigen (CA) 19-9 in colorectal cancer (CRC) patients to determine the prognostic value of CA19-9 in CRC patients with normal carcinoembryonic antigen (CEA) levels. Methods: A total of 639 patients who underwent curative surgery at Taipei Veterans General Hospital between 2002 and 2006 were enrolled. We excluded 254 patients (39.7 %) with high preoperative CEA levels and analyzed 385 patients with normal CEA levels. The measured endpoint was the postoperative disease-free survival (DFS). The prognostic value of CA19-9 was determined using logrank test and Cox regression analysis. Results: High CA19-9 levels were significantly associated with advanced disease and were detected in 5.8 % of patients with stage I disease, 11.7 % of those with stage II disease, and 22.5 % of those with stage III disease (P<0.001). The 5-year DFS in patients with normal CA19-9 levels was 82.0 %, which was significantly higher than that in patients with high CA19-9 levels (68 %; P<0.001). In a multivariate analysis, the most important independent factor affecting the 5-year DFS was tumor-node-metastasis stage (95 % CI, 1.26-2.36; HR01.72). After stratification by other factors, high CA19-9 level remained an independent prognostic factor for patients with normal CEA levels. Patients with high CA19-9 levels also showed a higher incidence of lung metastasis (23.1 %) than those with normal CA19-9 levels (7.2 %). Conclusions: CA19-9 may be a prognostic factor for CRC patients with normal CEA levels. An aggressive follow-up protocol for lung metastasis should be used for these patients.
机译:目的:我们回顾性分析大肠癌(CRC)患者的糖类抗原(CA)19-9的术前水平,以确定CA19-9在正常癌胚抗原(CEA)水平的CRC患者中的预后价值。方法:纳入2002年至2006年在台北荣民总医院接受根治性手术的639例患者。我们排除了术前CEA水平高的254例患者(39.7%),并分析了385例CEA水平正常的患者。测量的终点是术后无病生存期(DFS)。使用对数秩检验和Cox回归分析确定CA19-9的预后价值。结果:高CA19-9水平与晚期疾病显着相关,在5.8%的I期患者,11.7%的II期患者和22.5%的III期患者中检出(P <0.001)。正常CA19-9水平患者的5年DFS为82.0%,显着高于高CA19-9水平患者(68%; P <0.001)。在多变量分析中,影响5年DFS的最重要独立因素是肿瘤淋巴结转移阶段(95%CI,1.26-2.36; HR01.72)。经其他因素分层后,高CA19-9水平仍然是CEA水平正常患者的独立预后因素。高CA19-9水平的患者也显示出比具有正常CA19-9水平的患者(7.2%)更高的肺转移发生率(23.1%)。结论:CA19-9可能是CEA水平正常的CRC患者的预后因素。这些患者应采用积极的肺转移随访方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号